Abaxis Inc (ABAX) is Downgraded by Feltl & Co. to Sell

Abaxis Inc (ABAX) was Downgraded by Feltl & Co. to ” Sell”. Earlier the firm had a rating of “Hold ” on the company shares. Feltl & Co. advised their investors in a research report released on Jul 22, 2016.

On the company’s financial health, Abaxis Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.32. The company had revenue of $57.00 million for the quarter, compared to analysts expectations of $56.54 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.

Abaxis Inc opened for trading at $53.49 and hit $54.64 on the upside on Wednesday, eventually ending the session at $54.32, with a gain of 2.32% or 1.23 points. The heightened volatility saw the trading volume jump to 2,25,078 shares. Company has a market cap of $1,222 M.

In a different news, on Jun 10, 2016, Richard Bastiani (director) sold 5,000 shares at $46.73 per share price. According to the SEC, on May 19, 2016, Achim Henkel (Managing Director-Europe) sold 5,000 shares at $44.42 per share price. On May 11, 2016, Henk Evenhuis (director) sold 3,000 shares at $45.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Abaxis Inc. is a developer manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company operates through the two segments: the medical market and the veterinary market. The Company’s medical market customer group consists of physicians’ office practices across multiple specialties urgent care outpatient and walk-in clinics health screening operations home care providers and nursing homes. The Company’s medical market products include: Piccolo chemistry analyzers and consumable products. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs VetScan hematology instruments and related reagent kits VetScan VSpro specialty analyzers and related consumables VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Abaxis Inc

Leave a Reply

Abaxis Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abaxis Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.